Search - tctmd.com

Displaying 1 - 20 of 259

Sort: Relevancy | Date

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

News Conference News AHA 2025

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

November 09, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure ANDES

News Conference News TCT 2025

DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES

Yael L. Maxwell

November 04, 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

News Conference News EACTS 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

Yael L. Maxwell

October 13, 2025

ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation

News Conference News ESC 2025

ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation

September 08, 2025

Treatment Based on ABC-AF Risk Scores Doesn’t Improve AF Outcomes

News Conference News ESC 2025

Treatment Based on ABC-AF Risk Scores Doesn’t Improve AF Outcomes

September 08, 2025

AMALFI: Modest AF Detection With ECG Patch Screening

News Conference News ESC 2025

AMALFI: Modest AF Detection With ECG Patch Screening

Michael O'Riordan

September 05, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

No Benefit of Sentinel Device During TAVI: Updated Meta-analysis

News Conference News NY Valves 2025

No Benefit of Sentinel Device During TAVI: Updated Meta-analysis

July 04, 2025

High Residual Risk of Recurrent Stroke Seen in AF Patients on Anticoagulants

News Conference News ESOC 2025

High Residual Risk of Recurrent Stroke Seen in AF Patients on Anticoagulants

May 29, 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

March 12, 2025

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

News Conference News CRT 2025

SMART: Small Aortic Annuli Still Fare Best With Self-Expandable Valves at 2 Years

March 10, 2025

GFAP Biomarker Assay Can Discern ICH vs Ischemic Stroke

News Conference News ISC 2025

GFAP Biomarker Assay Can Discern ICH vs Ischemic Stroke

February 11, 2025

Amid Declining Use, Mechanical SAVR Valves Beat Bioprosthetic for Survival

News Conference News STS 2025

Amid Declining Use, Mechanical SAVR Valves Beat Bioprosthetic for Survival

Yael L. Maxwell

January 27, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.